240 related articles for article (PubMed ID: 28456731)
1. Different Involvement of OAT in Renal Disposition of Oral Anticoagulants Rivaroxaban, Dabigatran, and Apixaban.
Tsuruya Y; Nakanishi T; Komori H; Wang X; Ishiguro N; Kito T; Ikukawa K; Kishimoto W; Ito S; Schaefer O; Ebner T; Yamamura N; Kusuhara H; Tamai I
J Pharm Sci; 2017 Sep; 106(9):2524-2534. PubMed ID: 28456731
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein.
Margelidon-Cozzolino V; Hodin S; Jacqueroux E; Delézay O; Bertoletti L; Delavenne X
J Pharmacol Exp Ther; 2018 Jun; 365(3):519-525. PubMed ID: 29572341
[TBL] [Abstract][Full Text] [Related]
3. Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human Serum.
Boehr S; Haen E
Ther Drug Monit; 2017 Feb; 39(1):66-76. PubMed ID: 27861316
[TBL] [Abstract][Full Text] [Related]
4. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport.
Takeda M; Khamdang S; Narikawa S; Kimura H; Kobayashi Y; Yamamoto T; Cha SH; Sekine T; Endou H
J Pharmacol Exp Ther; 2002 Mar; 300(3):918-24. PubMed ID: 11861798
[TBL] [Abstract][Full Text] [Related]
5. In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants.
Jacqueroux E; Mercier C; Margelidon-Cozzolino V; Hodin S; Bertoletti L; Delavenne X
Fundam Clin Pharmacol; 2020 Feb; 34(1):109-119. PubMed ID: 31411766
[TBL] [Abstract][Full Text] [Related]
6. Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
Sciascia S; Radin M; Schreiber K; Fenoglio R; Baldovino S; Roccatello D
Intern Emerg Med; 2017 Dec; 12(8):1101-1108. PubMed ID: 28929298
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
Hellwig T; Gulseth M
Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of sixteen pharmaceutical excipients on six major organic cation and anion uptake transporters.
Ma R; Li G; Wang X; Bi Y; Zhang Y
Xenobiotica; 2021 Jan; 51(1):95-104. PubMed ID: 32544367
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives.
Ašić A; Marjanović D; Mirat J; Primorac D
Per Med; 2018 May; 15(3):209-221. PubMed ID: 29767545
[TBL] [Abstract][Full Text] [Related]
10. Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
Pan EY; Sobieraj DM
Conn Med; 2016 Feb; 80(2):105-11. PubMed ID: 27024982
[No Abstract] [Full Text] [Related]
11. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
Ufer M
Thromb Haemost; 2010 Mar; 103(3):572-85. PubMed ID: 20135071
[TBL] [Abstract][Full Text] [Related]
12. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
Stöllberger C; Finsterer J
Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425
[TBL] [Abstract][Full Text] [Related]
13. OAT3 Participates in Drug-Drug Interaction between Bentysrepinine and Entecavir through Interactions with M8-A Metabolite of Bentysrepinine-In Rats and Humans In Vitro.
Zhang A; Yang F; Yuan Y; Li C; Huo X; Liu J; Zhou S; Li W; Zhang N; Liu J; Dong S; Fan H; Peng Y; Zheng J
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838982
[TBL] [Abstract][Full Text] [Related]
14. Organic anion transporters involved in the excretion of bestatin in the kidney.
Zhu Y; Meng Q; Wang C; Liu Q; Sun H; Kaku T; Liu K
Peptides; 2012 Feb; 33(2):265-71. PubMed ID: 22273603
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Wong PC; White A; Luettgen J
Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
[TBL] [Abstract][Full Text] [Related]
16. Problem-Based Review: Non Vitamin K Antagonist Oral Anticoagulants for the Acute Physician.
Thachil J; Gagg J
Acute Med; 2015; 14(2):83-9. PubMed ID: 26305087
[TBL] [Abstract][Full Text] [Related]
17. Interactions of stevioside and steviol with renal organic anion transporters in S2 cells and mouse renal cortical slices.
Srimaroeng C; Jutabha P; Pritchard JB; Endou H; Chatsudthipong V
Pharm Res; 2005 Jun; 22(6):858-66. PubMed ID: 15948029
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters.
Hashimoto T; Narikawa S; Huang XL; Minematsu T; Usui T; Kamimura H; Endou H
Drug Metab Dispos; 2004 Oct; 32(10):1096-102. PubMed ID: 15377641
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid.
Tahara H; Kusuhara H; Maeda K; Koepsell H; Fuse E; Sugiyama Y
Drug Metab Dispos; 2006 May; 34(5):743-7. PubMed ID: 16455804
[TBL] [Abstract][Full Text] [Related]
20. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
